Overview

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

Status:
Completed
Trial end date:
2021-02-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Contraceptive Agents
Contraceptives, Oral
Tirzepatide